IP Library Granted Patent US 9,636,321
Granted Patent B2
US 9,636,321 · App. 15/081,898 · Granted May 2, 2017

Compositions and methods for treating psoriasis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,636,321
App. No.
15/081,898
Granted
May 2, 2017
Kind
B2
Abstract

Novel isohexides and pharmaceutical compositions containing the same as well as methods of using the same in the treatment of psoriasis.

Claims (24)

1. A compound according to the general formula (I):

in which R 1 and R 2 are both —CH═CH—COOMe or one of R 1 and R 2 are H and the other —CH═CH—COOMe.

2. The compound of claim 1 wherein R 1 and R 2 are the same.

3. The compound of claim 1 wherein R 1 and R 2 are not the same.

4. A pharmaceutical composition comprising one or more compounds of claim 1 in a pharmaceutically acceptable vehicle.

5. The pharmaceutical composition of claim 4 wherein R 1 and R 2 are the same.

6. The pharmaceutical composition of claim 4 wherein R 1 and R 2 are not the same.

7. The pharmaceutical composition of claim 4 further comprising at least one other pharmaceutical active.

8. The pharmaceutical composition of claim 7 wherein the at least one other pharmaceutical active is one or more compounds corresponding to the formula II or formula III or at least one of each:

wherein R 3 and R 4 which are the same or different, are independently selected from straight chain or branched; saturated or unsaturated alkyl groups having from 4 to 30 carbon atoms provided that when R 3 and R 4 are different, one of R 3 or R 4 is hydrogen or a straight chain or branched, saturated or unsaturated alkyl group of from 1 to 30 carbon atoms.

9. The pharmaceutical composition of claim 8 wherein the additional pharmaceutical active is of formula Ill and the alkyl groups of R 3 and R 4 have from 16 to 18 carbon atoms.

10. The pharmaceutical composition of claim 8 wherein the additional pharmaceutical active is isosorbide dilinoleate.

11. A method of therapeutically treating psoriasis comprising administering to the patient suffering therefrom an effective amount of a compound according to claim 1 .

12. The method of claim 11 wherein R 1 and R 2 are the same.

13. The method of claim 11 wherein R 1 and R 2 are not the same.

14. The method of claim 11 wherein the compound is a component of a pharmaceutical composition that is administered to the patient.

15. The method of claim 14 wherein the pharmaceutical composition is administered orally.

16. The method of claim 14 wherein the pharmaceutical composition is applied topically to those areas of the skin of a patient manifesting symptoms of psoriasis.

17. The method of claim 14 wherein the pharmaceutical composition further comprises at least one other pharmaceutical active.

18. The method of claim 17 wherein the at least one other pharmaceutical active is one or more compounds corresponding to the formulae II and/or III:

wherein R 3 and R 4 which are the same or different, are independently selected from straight chain or branched; saturated or unsaturated alkyl groups having from 4 to 30 carbon atoms provided that when R 3 and R 4 are different, one of R 3 or R 4 is hydrogen or a straight chain or branched, saturated or unsaturated alkyl group of from 1 to 30 carbon atoms.

19. The method of claim 18 wherein the additional pharmaceutical active is of formula III and the alkyl groups of R 3 and R 4 have from 16 to 18 carbon atoms.

20. The method of claim 17 wherein the additional pharmaceutical active is isosorbide dilinoleate.

21. A method of delaying the onset of symptoms of psoriasis in persons predisposed to the disease comprising administering to said persons a therapeutically effective amount of a compound according to claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2023
From: SYMBIONYX PHARMACEUTICALS INC
To: SYTHEON LTD
Reel/Frame 063182/0517 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2017
From: SYTHEON LTD
To: SYMBIONYX PHARMACEUTICALS INC
Reel/Frame 041503/0224 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2016
From: CHAUDHURI, RATAN K; BOJANOWSKI, KRYS
To: SYTHEON LIMITED
Reel/Frame 038486/0532 →